CGEN
Price
$1.41
Change
-$0.05 (-3.42%)
Updated
Apr 3 closing price
Capitalization
129.01M
34 days until earnings call
ERNA
Price
$0.18
Change
-$0.01 (-5.26%)
Updated
Apr 3 closing price
Capitalization
9.61M
Ad is loading...

CGEN vs ERNA

Header iconCGEN vs ERNA Comparison
Open Charts CGEN vs ERNABanner chart's image
Compugen
Price$1.41
Change-$0.05 (-3.42%)
Volume$276.64K
Capitalization129.01M
Ernexa Therapeutics
Price$0.18
Change-$0.01 (-5.26%)
Volume$321.58K
Capitalization9.61M
CGEN vs ERNA Comparison Chart
Loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CGEN vs. ERNA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and ERNA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CGEN: $1.41 vs. ERNA: $0.18)
Brand notoriety: CGEN and ERNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 65% vs. ERNA: 89%
Market capitalization -- CGEN: $129.01M vs. ERNA: $9.61M
CGEN [@Biotechnology] is valued at $129.01M. ERNA’s [@Biotechnology] market capitalization is $9.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 1 FA rating(s) are green whileERNA’s FA Score has 0 green FA rating(s).

  • CGEN’s FA Score: 1 green, 4 red.
  • ERNA’s FA Score: 0 green, 5 red.
According to our system of comparison, CGEN is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 4 TA indicator(s) are bullish while ERNA’s TA Score has 4 bullish TA indicator(s).

  • CGEN’s TA Score: 4 bullish, 4 bearish.
  • ERNA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CGEN and ERNA are a good buy in the short-term.

Price Growth

CGEN (@Biotechnology) experienced а -7.24% price change this week, while ERNA (@Biotechnology) price change was -20.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

CGEN is expected to report earnings on May 08, 2025.

ERNA is expected to report earnings on May 11, 2023.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CGEN($129M) has a higher market cap than ERNA($9.61M). CGEN YTD gains are higher at: -7.843 vs. ERNA (-38.435). CGEN has higher annual earnings (EBITDA): -14.41M vs. ERNA (-36.12M). CGEN has more cash in the bank: 103M vs. ERNA (1.73M). ERNA has less debt than CGEN: ERNA (684K) vs CGEN (2.91M). CGEN has higher revenues than ERNA: CGEN (27.9M) vs ERNA (582K).
CGENERNACGEN / ERNA
Capitalization129M9.61M1,342%
EBITDA-14.41M-36.12M40%
Gain YTD-7.843-38.43520%
P/E Ratio64.00N/A-
Revenue27.9M582K4,794%
Total Cash103M1.73M5,957%
Total Debt2.91M684K426%
FUNDAMENTALS RATINGS
CGEN vs ERNA: Fundamental Ratings
CGEN
ERNA
OUTLOOK RATING
1..100
5750
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
59
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
8496
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
1350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (59) in the Medical Specialties industry is in the same range as CGEN (78) in the Biotechnology industry. This means that ERNA’s stock grew similarly to CGEN’s over the last 12 months.

ERNA's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as CGEN (100) in the Biotechnology industry. This means that ERNA’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (95) in the Biotechnology industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that CGEN’s stock grew similarly to ERNA’s over the last 12 months.

CGEN's Price Growth Rating (84) in the Biotechnology industry is in the same range as ERNA (96) in the Medical Specialties industry. This means that CGEN’s stock grew similarly to ERNA’s over the last 12 months.

CGEN's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for ERNA (100) in the Medical Specialties industry. This means that CGEN’s stock grew significantly faster than ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENERNA
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
71%
Stochastic
ODDS (%)
N/A
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
83%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SBMBX12.23N/A
N/A
Saratoga Energy & Basic Materials A
NGRRX30.57N/A
N/A
Nuveen International Value I
DLBMX16.02N/A
N/A
MassMutual Small Cap Opps A
CVMAX17.65N/A
N/A
Calvert Emerging Markets Equity A
RTNSX12.04N/A
N/A
Russell Inv Tax-Managed Intl Eq S

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NURPF. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NURPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
-3.42%
NURPF - CGEN
46%
Loosely correlated
N/A
ASPHF - CGEN
41%
Loosely correlated
N/A
ORMP - CGEN
40%
Loosely correlated
-1.82%
AXON - CGEN
36%
Loosely correlated
-3.35%
BPMC - CGEN
36%
Loosely correlated
-3.22%
More

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-5.24%
CGEN - ERNA
39%
Loosely correlated
-3.42%
MDGL - ERNA
36%
Loosely correlated
-2.24%
IBIO - ERNA
32%
Poorly correlated
-7.77%
SMMT - ERNA
31%
Poorly correlated
-7.58%
CYTK - ERNA
29%
Poorly correlated
+0.67%
More